Search Results for “FDA” – Page 168 – media

Shingrix Orders Limited by GlaxoSmithKline

Order limits have been introduced by GSK owing to high demand for the product, as per a note on the CDC’s website. In the meantime, shipping delays are being experienced by providers and according to the CDC, the delays are likely to remain throughout the year.
- Source: FiercePharma
- 674
- June 22, 2018
GSK Market Views shingles
Remote Patient Monitoring Startup could Spell Major Turning Point in Digital Health

Ambient Clinical Analytics, the remote patient monitoring firm which became independent from Mayo Clinic in 2013, has elevated $1.5 million in a round led by Noaber Ventures. Noaber Ventures is the extended investment arm of Noaber Foundation and the company’s first European investor. The already existing investors such as Mayo Clinic, Bluestem Capital and Social Capital have also contributed to the round.
- Source: MobiHealthNews
- 704
- June 22, 2018
Company Insight digital health EHR
Toothpaste Combats Lung Disease

Cystic fibrosis is the most common lung affecting genetic disease, which often turns out to be life-threatening. Nearly one in every 2500 to 3500 people are diagnosed with cystic fibrosis at an early age. A thick mucus formation in the lungs becomes stuck to bacteria, which leads to a slimy biofilm formation.
- Source: India Times
- 507
- June 21, 2018
cystic fibrosis Researches
Salmonella Warning for Cut Melons

Fresh cut melons sold at popular grocery stores were responsible for nearly 60 people being infected with Salmonella. In order to be sure of what is safe to consume and what not, refer to the list of Food and Drug Administration (FDA) consumable items. Here they state that people need not give up melons entirely but rather only the pre-cut ones.
- Source: HealthLine
- 550
- June 20, 2018
Researches Salmonella
One More Approval for Merck’s Keytruda

On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
- Source: Fierce Pharma
- 716
- June 15, 2018
cancer Merck New Approvals non-Hodgkin lymphoma
Airo CT Imaging For Pediatrics

It has been reported that the FDA has granted the approval of Mobius Imaging, LLC based Airo CT imaging utilization for pediatric patients. These pediatric patients can receive the clinical benefits of Airo CT imaging for diagnostic and intraoperative procedures hereafter.
- Source: MPO mag
- 775
- June 13, 2018
CT scanner medical device New Approvals
Emergent BioSolutions to Invest $50M for Expansion

Emergent BioSolutions, Gaithersburg, Maryland-based Biopharmaceutical Company announced that it will invest $50 million for the next three years to expand the manufacturing capacity for its Camden fill-finish in Baltimore facility. By the time the project has been completed in three years, it is expected to add up 60 jobs.
- Source: FiercePharma
- 783
- June 11, 2018
biopharmaceutical Company Insight
Hospira Inc. Recalls Opioid Antidote Naloxone

According to the FDA, if the antidote drugs are used on a patient, they could suffer from “allergic reactions, local irritation” and a wide number of cardiovascular issues, including restriction of blood supply to tissues. The FDA stated that there has not yet been any reports of patient harm from Naloxone.
- Source: Ddu
- 610
- June 7, 2018
Company Insights FDA opioid
Lynparza and Zytiga Combo Effective Against Prostate Cancer

Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
- Source: Ddu
- 764
- June 6, 2018
AstraZeneca Clinical Trials Company Insight prostate cancer
New Hope For Osteoporosis, SLIT3 Protein Molecule To Advance Bone Blood Vessels

Weill Cornell’s Medicine scientist claim to have discovered a new treatment for osteoporosis, which targets the blood vessels inside of bone, a molecule that promotes the growth of those blood vessels and reverses the weakening of bones and helps fracture, heals.
- Source: Ddu
- 650
- May 29, 2018
osteoporosis Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.